Back

Is acetazolamide a potential intervention for people with bipolar disorders? A scoping review protocol.

Strawbridge, R.; Orfanos, S.; Yalin, N.; Young, A. H.

2022-08-30 psychiatry and clinical psychology
10.1101/2022.08.27.22279292 medRxiv
Show abstract

Acetazolamide is a carbonic anhydrase inhibitor whose primary indication is to alleviate altitude sickness, but it is also used in the treatment of glaucoma, seizures and oedema. Although it has not been repurposed for psychiatric illnesses, acetazolamide has been advocated for its putative benefits in those with a bipolar disorder (BD). Because current treatment options for BD bring a variety of challenges, it is important to examine the current evidence to date in a formal synthesis. This article describes a protocol for a scoping review to do so, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews (PRISMA-ScR). PubMed, Embase and PsycInfo will be searched for all available publications focusing on the intervention acetazolamide for people with BD. This will include non-primary and primary research of any design, focusing on any outcome, in order to comprehensively bring together the work that has been undertaken to date on this topic. Relevant data from included articles will be subject to a narrative synthesis. It is anticipated that the results from the review will help to ascertain the potential for acetazolamide to benefit people with bipolar affective disorders in the future and aid the planning of future primary research to establish this.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.